XML 15 R5.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
shares in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income
Accumulated Deficit
Beginning Balance at Dec. 31, 2018 $ 7,157,000 $ 2,000 $ 243,022,000   $ (235,867,000)
Beginning Balance, shares at Dec. 31, 2018   2,148      
Issuance of common stock for release of awards (1,000)   (1,000)    
Issuance of common stock for release of awards, shares   9      
Stock-based compensation (4,000)   (4,000)    
Net income (loss) 10,000       10,000
Ending Balance at Mar. 31, 2019 7,162,000 $ 2,000 243,017,000   (235,857,000)
Ending Balance, shares at Mar. 31, 2019   2,157      
Beginning Balance at Dec. 31, 2018 7,157,000 $ 2,000 243,022,000   (235,867,000)
Beginning Balance, shares at Dec. 31, 2018   2,148      
Unrealized gain on available-for-sale investments 1,000        
Net income (loss) (93,000)        
Ending Balance at Jun. 30, 2019 7,179,000 $ 2,000 243,136,000 $ 1,000 (235,960,000)
Ending Balance, shares at Jun. 30, 2019   2,162      
Beginning Balance at Mar. 31, 2019 7,162,000 $ 2,000 243,017,000   (235,857,000)
Beginning Balance, shares at Mar. 31, 2019   2,157      
Issuance of common stock for release of awards, shares   5      
Stock-based compensation 119,000   119,000    
Unrealized gain on available-for-sale investments 1,000     1,000  
Net income (loss) (103,000)       (103,000)
Ending Balance at Jun. 30, 2019 7,179,000 $ 2,000 243,136,000 $ 1,000 (235,960,000)
Ending Balance, shares at Jun. 30, 2019   2,162      
Beginning Balance at Dec. 31, 2019 $ 4,836,000 $ 2,000 243,281,000   (238,447,000)
Beginning Balance, shares at Dec. 31, 2019 2,179 2,179      
Issuance of common stock for release of awards $ (1,000)   (1,000)    
Issuance of common stock for release of awards, shares   20      
Exercise of pre-funded warrants 2,000   2,000    
Exercise of pre-funded warrants, shares   116      
Stock-based compensation 68,000   68,000    
Net income (loss) (1,405,000)       (1,405,000)
Ending Balance at Mar. 31, 2020 3,500,000 $ 2,000 243,350,000   (239,852,000)
Ending Balance, shares at Mar. 31, 2020   2,315      
Beginning Balance at Dec. 31, 2019 $ 4,836,000 $ 2,000 243,281,000   (238,447,000)
Beginning Balance, shares at Dec. 31, 2019 2,179 2,179      
Deemed dividend for warrant exercise price adjustment $ 392,000        
Net income (loss) (2,044,000)        
Ending Balance at Jun. 30, 2020 $ 4,546,000 $ 3,000 245,426,000   (240,883,000)
Ending Balance, shares at Jun. 30, 2020 3,534 3,534      
Beginning Balance at Mar. 31, 2020 $ 3,500,000 $ 2,000 243,350,000   (239,852,000)
Beginning Balance, shares at Mar. 31, 2020   2,315      
Issuance of common stock for release of awards, shares   1      
Sale of common stock, net of financing costs 1,619,000 $ 1,000 1,618,000    
Sale of common stock, net of financing costs, shares   1,218      
Deemed dividend for warrant exercise price adjustment 392,000   392,000   (392,000)
Stock-based compensation 66,000   66,000    
Net income (loss) (639,000)       (639,000)
Ending Balance at Jun. 30, 2020 $ 4,546,000 $ 3,000 $ 245,426,000   $ (240,883,000)
Ending Balance, shares at Jun. 30, 2020 3,534 3,534